An Open, Single-Center,Single Arm Trial to Evaluate the Efficacy and Safety of Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Trial Profile

An Open, Single-Center,Single Arm Trial to Evaluate the Efficacy and Safety of Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Suspended
Phase of Trial: Phase IV

Latest Information Update: 27 May 2015

At a glance

  • Drugs Icotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Zhejiang Beta Pharma
  • Most Recent Events

    • 26 Jun 2014 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
    • 08 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 20 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top